Stratification and monitoring of natalizumabassociated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 2, 2016, Pages 117-125

  McGuigan, C ^a   Craner, M ^b   Guadagno, J ^c   Kapoor, R ^d   Mazibrada, G ^e   Molyneux, P ^f   Nicholas, R ^g   Palace, J ^b   Pearson, O R ^h   Rog, D ⁱ   Young, C A ^j  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c ROYAL VICTORIA INFIRMARY   (United Kingdom)

^d NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f WEST SUFFOLK HOSPITAL   (United Kingdom)

^g CHARING CROSS HOSPITAL   (United Kingdom)

^h ABERTAWE BRO MORGANNWG UNIVERSITY HEALTH BOARD   (United Kingdom)

ⁱ SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^j THE WALTON CENTRE NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; VIRUS ANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; ASYMPTOMATIC DISEASE; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG USE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CODING; PATIENT MONITORING; PATIENT RISK; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TREATMENT DURATION; TREATMENT OUTCOME; AMBULATORY MONITORING; CHEMICALLY INDUCED; COMPLICATION; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; RISK;

GUIDELINES AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MONITORING, AMBULATORY; MULTIPLE SCLEROSIS; NATALIZUMAB; RISK;

EID: 84958977773     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-311100     Document Type: Article

References (55)

1. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 2011;10:745-58.
2. Kappos L, Radue EW, O'Connor P, et al., FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
3. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
4. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28.
5. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39.
6. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 2013;80:1430-8.
7. Blair NF, Brew BJ, Halpern JP. Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance. Neurology 2012;78:507-8.
8. Lindå H, von Heijne A. Presymptomatic diagnosis with MRI and adequate treatment ameliorate the outcome after natalizumab-associated progressive multifocal leukoencephalopathy. Front Neurol 2013;4:11.
9. Mc Govern E, Hennessy M. Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab. J Neurol 2013;260:665-7.
10. Phan-Ba R, Belachew S, Outteryck O, et al. The earlier, the smaller, the better for natalizumab-associated PML: In MRI vigilance veritas? Neurology 2012;79:1067-9.
11. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry 2012;83:224-6.
12. Dong-Si T, Richman S, Wattjes MP, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol 2014;1:755-64.
13. Biogen. Tysabri 300 mg concentrate for solution for infusion. Summary of medical product characteristics. http://www.medicines.org.uk/EMC/medicine/18447/SPC/TYSABRI+300+mg+concentrate+for+solution+for+infusion/(accessed 24 Jun 2015).
14. Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract Neurol 2012;12:25-35.
15. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 2012;18:143-52.
16. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:802-12.
17. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2013;19:1826-40.
18. Bozic C, Subramanyam M, Richman S, et al. Anti-JC virus ( JCV) antibody prevalence in the JCV Epidemiology in MS ( JEMS) trial. Eur J Neurol 2014;21:299-304.
19. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
20. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010;68:295-303.
21. Biogen. Physician Information and Management Guidelines for Multiple Sclerosis Patients on TYSABRI Therapy. Version 14. Maidenhead: Biogen 2015.
22. Brosseau M-S, Stobbe G, Cramer D, et al. Natalizumab-Related PML Is Possible Even With Recent Negative JCV Antibody Testing. Poster presented at the 67th American Academy of Neurology Annual Meeting April 18-25, Washington DC, USA, 2015. http://www.abstracts2view.com/aan/view.php?nu=AAN15L1-P4.030
23. EMA. (European Medicines Agency). Tysabri: Procedural steps taken and scientific information after authorisation. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Procedural-steps-taken-and-scientific-information- after-authorisation/human/000603/WC500044692.pdf (accessed 24 Jun 2015).
24. Fine AJ, Sorbello A, Kortepeter C, et al. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann Neurol 2014;75:108-15.
25. Gheuens S, Smith DR, Wang X, et al. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 2012;78:1390-3.
26. Outteryck O, Zéphir H, Salleron J, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler 2014;20:822-9.
27. Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013;84:1199-205.
28. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012;78:1736-42.
29. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody status in MS patients: baseline results of STRATIFY-2. Poster presented at the 26th Annual Meeting of the Consortium of Multiple Sclerosis Centers, Orlando, FL, USA; May 30-June 2, 2012. Poster No. DX71 http://cmsc.omnibooksonline.com/2012/index.html (accessed 24 Jun 2015).
30. Raffel J, Gafson A, Malik O, et al. Anti-JC virus antibody titres increase over time with natalizumab treatment. Mult Scler 2015 (Accepted for publication). doi:10.1177/1352458515599681.
31. Vennegoor A, van Rossum JA, Polman CH, et al. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler 2015;21:1600-3.
32. Kuesters G, Plavina T, Lee S, et al. Anti-JC virus ( JCV) Antibody Index Differentiates Risk of Progressive Multifocal Leukoencephalopathy in Natalizumab-treated Multiple Sclerosis Patients with no Prior Immunosuppressant Use: an Updated Analysis Poster presented at the 67th American Academy of Neurology Annual Meeting April 18-25, Washington DC, USA. http://www.abstracts2view.com/aan/view.php? nu=AAN15L1-P4.031
33. Clifford DB, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-46.
34. Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 2013;84:1068-74.
35. Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol 2015. (Accepted for publication) doi: 10. 1007/s13365-015-0316-4.
36. Ayzenberg I, Lukas C, Trampe N, et al. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy. J Neurol 2012;259:1732-3.
37. Focus. Diagnostics. STRATIFY JCV DxSelectTM: Enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of human antibodies to JC virus. CA, USA: Focus Diagnostics, Cypress, 2013. http://www.focusdx.com/pdfs/pi/US/EL1950.pdf (accessed 24 Jun 2015).
38. Nicholas JA, Racke MK, Imitola J, et al. First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks. Ther Adv Chronic Dis 2014;5:62-8.
39. Berger JR, Houff SA, Gurwell J, et al. JC virus antibody status underestimates infection rates. Ann Neurol 2013;74:84-90.
40. Frohman EM, Monaco M, Remington G, et al. JC virus in cd34+ and cd19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol 2014;71:596-602.
41. Lindå H, von Heijne A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009;361:1081-7.
42. Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology 2011;76:574-6.
43. Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2012;72:779-87.
44. Richert N, Bloomgren G, Cadavid D, et al. Imaging findings for PML in natalizumab-treated MS patients. Mult Scler 2012;18(suppl 4):27-8. Oral 99.
45. Wattjes MP, Vennegoor A, Steenwijk MD, et al. MRI pattern in asymptomatic natalizumab-associated PML. J Neurol Neurosurg Psychiatry 2015;86:793-8.
46. de Toffol B, Vidailhet M, Gray F, et al. Isolated motor control dysfunction related to progressive multifocal leukoencephalopathy during AIDS with normal MRI. Neurology 1994;44:2352.
47. Agnihotri SP, Dang X, Carter JL, et al. JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene. Neurology 2014;83:727-32.
48. Schippling S, Kempf C, Büchele F, et al. JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol 2013;74:622-6.
49. Wijburg M, van Oosten B, Murk JL, et al. Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature. J Neurol 2015;262:65-73.
50. Taieb G, Renard D, Thouvenot E, et al. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy. J Neurol Sci 2014;346:364-5.
51. Warnke C, von Geldern G, Markwerth P, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014;76:792-801.
52. Wattjes M, Vennegoor A, Mostert J, et al. Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place? J Neurol 2014;261:1139-43.
53. Mentzer D, Prestel J, Adams O, et al. Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies. J Neurol Neurosurg Psychiatry 2012;83:927-33.
54. Kuhle J, Gosert R, Bühler R, et al. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 2011;77:2010-16.
55. Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:1061-7.